HomeCompareHILS vs XYLD

HILS vs XYLD: Dividend Comparison 2026

HILS yields 843.88% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HILS wins by $4363248.77M in total portfolio value
10 years
HILS
HILS
● Live price
843.88%
Share price
$0.24
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4363248.80M
Annual income
$3,538,417,394,347.70
Full HILS calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — HILS vs XYLD

📍 HILS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHILSXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HILS + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HILS pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HILS
Annual income on $10K today (after 15% tax)
$71,729.96/yr
After 10yr DRIP, annual income (after tax)
$3,007,654,785,195.55/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, HILS beats the other by $3,007,654,782,459.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HILS + XYLD for your $10,000?

HILS: 50%XYLD: 50%
100% XYLD50/50100% HILS
Portfolio after 10yr
$2181624.41M
Annual income
$1,769,208,698,783.36/yr
Blended yield
81.10%
📊

Analyst Conviction Gap

Where Wall Street is split right now

HILS
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-0.3
Piotroski
2/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HILS buys
0
XYLD buys
0
No recent congressional trades found for HILS or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHILSXYLD
Forward yield843.88%10.98%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4363248.80M$25.3K
Annual income after 10y$3,538,417,394,347.70$3,219.02
Total dividends collected$4298592.53M$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: HILS vs XYLD ($10,000, DRIP)

YearHILS PortfolioHILS Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$95,088$84,388.19$10,818$1,098.39+$84.3KHILS
2$851,681$749,936.40$11,738$1,222.51+$839.9KHILS
3$7,188,859$6,277,560.82$12,774$1,364.64+$7.18MHILS
4$57,213,181$49,521,101.51$13,944$1,527.86+$57.20MHILS
5$429,552,802$368,334,698.45$15,270$1,715.87+$429.54MHILS
6$3,044,138,048$2,584,516,550.07$16,775$1,933.09+$3044.12MHILS
7$20,374,845,574$17,117,617,861.98$18,490$2,184.87+$20374.83MHILS
8$128,876,441,910$107,075,357,146.57$20,450$2,477.63+$128876.42MHILS
9$770,870,472,639$632,972,679,795.13$22,697$2,819.19+$770870.45MHILS
10$4,363,248,800,072$3,538,417,394,347.70$25,280$3,219.02+$4363248.77MHILS

HILS vs XYLD: Complete Analysis 2026

HILSStock

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Full HILS Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this HILS vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HILS vs SCHDHILS vs JEPIHILS vs OHILS vs KOHILS vs MAINHILS vs QYLDHILS vs JEPQHILS vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.